Log in to save to my catalogue

A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administere...

A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administere...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2480493689

A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON study

About this item

Full title

A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON study

Publisher

Singapore: Springer Singapore

Journal title

International journal of clinical oncology, 2021-05, Vol.26 (5), p.941-950

Language

English

Formats

Publication information

Publisher

Singapore: Springer Singapore

More information

Scope and Contents

Contents

Purpose
Fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX, FFX) and gemcitabine plus
nab
-paclitaxel (GnP) are considered standard treatments for patients with metastatic pancreatic cancer. Direct comparisons are not available that establish which is optimal.
Methods
We conducted a propensity score-adjusted analysis o...

Alternative Titles

Full title

A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON study

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2480493689

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2480493689

Other Identifiers

ISSN

1341-9625

E-ISSN

1437-7772

DOI

10.1007/s10147-021-01859-2

How to access this item